EUVIMEDEUVIMED entdecken
Crossref

Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer

Donald Richards, Ruizhi Zhao, Nadeem Khan, Brenda Chang, Siraje Mahmud, Tehseen Salimi

NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026

DOI: 10.67209/ywzs9808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Donald Richards und 5 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trifluridine/tipiracil (FTD-TPI; LONSURF) is an oral antineoplastic agent approved for 3rd-line use in combination with or without bevacizumab (BEV) in metastatic colorectal cancer (mCRC). In the Phase III SUNLIGHT trial, the addition of BEV to FTD-TPI was associated with a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to FTD-TPI monotherapy. However, data on the use of FTD-TPI in combination with BEV in the real-world community setting are currently limited.

Zitieren

APA

Richards, D., Zhao, R., Khan, N., Chang, B., Mahmud, S., & Salimi, T. (2026). Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/ywzs9808

Vancouver

Richards D, Zhao R, Khan N, Chang B, Mahmud S, Salimi T. Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/ywzs9808

BibTeX
@article{Richards2026,
  author = {Richards, Donald and Zhao, Ruizhi and Khan, Nadeem and Chang, Brenda and Mahmud, Siraje and Salimi, Tehseen},
  title = {Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/ywzs9808}
}
Kostenlos starten →